SLC6A3 and Parkinson disease: Our findings suggest that the istradefylline-induced epigenetic suppression of A2A receptor upregulation may have interesting implications for the fundamental goals of LD therapy, although many areas remain to be investigated, including PET imaging of dopamine transporters and A2A receptors in patients with PD receiving long-term istradefylline treatment [29–35].